Calquense for CLL – pro
There is support for acalabrutinib for CLL that failed ibrutinb based on a study presented at the 2016 ASH Annual Meeting for patients who no longer take ibrutinib because they have intolerance. It is one of the approaches to take with this regimen.It would be off-label because there is no current FDA approval for CLL yet. NCCN lists it for relapsed, refractory CLL. Dr. Byrd published data the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.
nccn, scll-e, 2018
John C. Byrd, M.D., Bonnie Harrington, D.V.M., Susan O’Brien, M.D., Jeffrey A. Jones, M.D., M.P.H., Anna Schuh, M.D., Ph.D., Steve Devereux, M.D., Jorge Chaves, M.D., William G. Wierda, M.D., Ph.D., Farrukh T. Awan, M.D., Jennifer R. Brown, M.D., Ph.D., Peter Hillmen, M.B., Ch.B., Ph.D., Deborah M. Stephens, D.O., Paolo Ghia, M.D., Jacqueline C. Barrientos, M.D., John M. Pagel, M.D., Ph.D., Jennifer Woyach, M.D., Dave Johnson, B.S., Jane Huang, M.D., Xiaolin Wang, Sc.D., Allard Kaptein, Ph.D., Brian J. Lannutti, Ph.D., Todd Covey, B.A., Maria Fardis, Ph.D., Jesse McGreivy, M.D., Ahmed Hamdy, M.B., B.Ch., Wayne Rothbaum, M.A., Raquel Izumi, Ph.D., Thomas G. Diacovo, M.D., Amy J. Johnson, Ph.D., and Richard R. Furman, M.D.et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Acalabrutinib, Prescribing Information 2018